Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

18. Mai 2017 06:30 ET | Quelle: ObsEva SA

ObsEva Announces the Completion of a Phase 1 Drug-Drug Interaction Study with OBE022

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} - OBE022 is ObsEva's potential...
16. Mai 2017 07:00 ET | Quelle: ObsEva SA

ObsEva SA to Attend BioEquity Europe 2017 in Paris

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland - 16 May 2017 -...
11. Mai 2017 07:00 ET | Quelle: ObsEva SA

ObsEva SA to Hold First Quarter 2017 Financial Results and Business Update Call on Thursday, May 18, 2017

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland and Boston, MA -...
25. April 2017 07:00 ET | Quelle: ObsEva SA

ObsEva SA Initiates Phase 3 Clinical Program for OBE2109 in Uterine Fibroids

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} - PRIMROSE 1 and PRIMROSE 2, pivotal...
24. März 2017 12:00 ET | Quelle: ObsEva SA

ObsEva SA to Attend Needham Annual Healthcare Conference in NYC

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland - 24 March 2017 -...
17. März 2017 07:00 ET | Quelle: ObsEva SA

ObsEva to Present Pharmacology Results Demonstrating OBE022 Exerts a Synergistic Effect in Combination with Standard of Care in Animal Model for Preterm Labor

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} - OBE022 is ObsEva's potential...
07. März 2017 07:00 ET | Quelle: ObsEva SA

ObsEva Starts Phase 3 Clinical Program for Nolasiban in ART

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} - IMPLANT2 study to confirm efficacy and...
03. Februar 2017 07:00 ET | Quelle: ObsEva SA

ObsEva SA to Attend LEERINK Partners Global Healthcare Conference in NYC

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland - February 03,...
25. Januar 2017 22:56 ET | Quelle: ObsEva SA

ObsEva SA Announces Pricing of Initial Public Offering

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland - January 25, 2017 -...
17. Januar 2017 05:00 ET | Quelle: ObsEva SA

ObsEva Expands Leadership Team and Board of Directors with Industry Veterans

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland, 17 January 2017 -...

Vorherige Seite

Nächste Seite